The Motley Fool

Why I’d buy GSK shares despite the coming dividend cut

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Owning GlaxoSmithKline (LSE: GSK) shares has been somewhat disappointing for many long-term investors. And with a dividend cut looming, some have decided it’s time to sell up.

However, despite the underwhelming past performance, I personally think the future could be a lot brighter. Indeed, I reckon now could be an opportune time for me to buy the stock. Here, I’ll explain my thinking.

One Killer Stock For The Cybersecurity Surge

Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028more than double what it is today!

And with that kind of growth, this North American company stands to be the biggest winner.

Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…

We think it has the potential to become the next famous tech success story. In fact, we think it could become as big… or even BIGGER than Shopify.

Click here to see how you can uncover the name of this North American stock that’s taking over Silicon Valley, one device at a time…

Poor performance of GSK shares

It’s a sad fact that GSK’s all-time-high share price (over £23) was as long ago as January 1999. This was almost two years before the Glaxo Wellcome/SmithKline Beecham merger that formed the platform of the group we know today. The share price hasn’t come near £23 in the 21st century. And I can currently buy the shares for little more than £14.

Returns for investors over the last five and 10 years have been inferior to the FTSE 100. On an annualised basis, 5.6% versus 7.2% (over five years) and 5.7% versus 6% (over 10 years). These returns include dividends. And as GSK’s annual payout has been stuck at 80p a share since 2014, investors who bought for income have seen their spending power nibbled away each year by inflation.

This may not seem a promising backdrop for me to buy GSK’s shares today. But as I mentioned, I think the future could be a lot brighter, despite the coming dividend cut.

GSK and GSK Consumer Healthcare shares

GSK is planning to split itself into two companies next year, and the dividend cut will accompany this. Many analysts and institutional shareholders have long felt the market is applying a ‘conglomerate discount’ to GSK. In other words, that its pharmaceuticals, vaccines and consumer healthcare businesses would be valued more highly by the market if they were standalone companies.

By buying GSK shares today, I could benefit from an uplift if the group’s demerger of its consumer healthcare business unlocks value. Of course, there’s no guarantee the aggregate value of the shares I would hold in the two companies would be higher than today’s £14. Indeed, there’s a risk it could be lower. The market could respond unfavourably when it gets more detail on the new corporate structures and dividend policies of the standalone companies.

GSK will be providing an investor update for shareholders on Wednesday (23 June). This is to outline strategy, growth outlooks (2022-2031), capital allocation priorities and timing and approach to separation.” The unveiling of its dividend plans is also on the agenda.


GSK has already said it expects the aggregate dividend of the two companies to be less than the current 80p. In an article back in February, my Motley Fool colleague Cliff D’Arcy noted analysts were forecasting 67p (a 16% reduction).

Today, the company-compiled consensus on GSK’s website is 54.6p (a 32% reduction), giving a yield of 3.8% on the current share price. Of course, the analyst consensus could prove to be too optimistic or too pessimistic. As such, there’s a risk I could be in for a lower dividend.

Still, despite the current areas of uncertainty and risks I’ve mentioned, I’d be happy to buy GSK shares today. Ultimately, I think the separation will unlock value. And that the standalone businesses can thrive with energised and focused management.

Our 5 Top Shares for the New “Green Industrial Revolution"

It was released in November 2020, and make no mistake:

It’s happening.

The UK Government’s 10-point plan for a new “Green Industrial Revolution.”

PriceWaterhouse Coopers believes this trend will cost £400billion…

…That’s just here in Britain over the next 10 years.

Worldwide, the Green Industrial Revolution could be worth TRILLIONS.

It’s why I’m urging all investors to read this special presentation carefully, and learn how you can uncover the 5 companies that we believe are poised to profit from this gargantuan trend ahead!

Access this special "Green Industrial Revolution" presentation now

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.